Do you have 

Liver Cirrhosis?

Liver cancer rates are increasing in the United States, and elsewhere. Out of every 100 patients with liver cancer, only 18 will survive for 5 years or more. An important cause of liver cancer is liver cirrhosis, which results from hepatitis infections, fatty liver, or alcohol use. Currently, there are no known preventive medications that could reduce the risk of liver cancer in people with cirrhosis.

 
 

Simvastatin in Preventing Liver Cancer in Patients with Liver Cirrhosis

Principal Investigator: Marc T. Goodman, Ph.D, M.P.H.
Cedars-Sinai Medical Center

This study will test the effects of simvastatin in people with liver cirrhosis. Participants in this study will get either simvastatin or placebo, a pill that looks like the study drug but contains no medication. This will allow researchers to see if participants taking simvastatin show changes in their liver, which may indicate a lower risk of developing cancer. This study is looking for volunteers who are 18 years of age or older and have liver cirrhosis. We will enroll 80 participants.

 

You may be eligible if you:

  • Are someone with a diagnosis of liver cirrhosis

  • Have never taken a statin medication before

 

You may be reimbursed up to $450 for your time and participation in this study.

 

If you think you may be eligible, you can contact a study coordinator at your preferred location from the list below:

CEDARS-SINAI MEDICAL CENTER– Los Angeles, California

UNIVERSITY OF PUERTO RICO – San Juan, Puerto Rico

GEORGETOWN UNIVERSITY – Washington, D.C.

Additional Resources

Study Brochure 

Cedars-Sinai Medical Center

Study Brochure 

Northwestern University

Statins & Liver Health 

Estatinas y salud hepática

 

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Patients With Cirrhosis

Principal Investigator: A. Ruth He, M.D.

Georgetown University

This study uses different doses of Polyphenon E® in people with liver cirrhosis. We want to see whether this green tea extract can decrease the level of a molecule called γ-OHPdG, that we think is an indicator of liver cancer risk.  Participants will undergo a liver biopsy before and after treatment. 50 participants will be registered for this study.

 

You may be eligible if you:

  • Are someone with a diagnosis of liver cirrhosis

  • Are over the age of 18

 

You may be compensated up to $1200 for your participation, your time, and extra expenses (child care, travel, absence from work, etc).

 

If you think you may be eligible, you can contact a study coordinator at your preferred location from the list below:

GEORGETOWN UNIVERSITY MEDICAL CENTER – Washington, D.C.

UNIVERSITY OF PUERTO RICO COMPREHENSIVE CANCER CENTER – San Juan, Puerto Rico

Content on NUcancerprevention.org is a courtesy from the Northwestern Cancer Prevention Consortium at Northwestern University. While we strive to maintain the most current and up to date information possible, NCPC does not guarantee accuracy, completeness, or relevance of the information supplied. The thoughts, views, and information found here do not necessarily reflect the views of Northwestern University or Northwestern Medicine. 

©2023 by Northwestern Cancer Prevention Consortium.